Women's imaging firm Hologic is touting six-year follow-up results from the American Society of Breast Surgeons (ASBS) MammoSite Registry Study.
The study of more than 1,400 patients shows "excellent/good" cosmetic results in 90.4% of the cases, the company said.
Dr. Peter Beitsch, a surgeon at the Dallas Breast Center and lead author of the study, said that positive data from the MammoSite Registry has contributed to the acceptance of accelerated partial-breast irradiation (APBI) across the U.S. and the world.
Results were presented at the American Society for Radiation Oncology (ASTRO) meeting in Miami Beach, FL, this week.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
